CRDF - NASDAQ

Cardiff Oncology, Inc.

CRDF·NASDAQ

$1.51

+7.5%

HealthcareBiotechnology

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$103.24M

EPS-0.6900

P/E Ratio-2.19

Earnings Date07/30/2026

61.88M

Assets

-36%

3Y-47.0%

5Y-54.0%

10Y+41.0%

16.50M

Total Liabilities

16%

3Y+68.0%

5Y+151.0%

10Y-32.0%

45.39M

Total Equity

-45%

3Y-57.0%

5Y-65.0%

10Y+130.0%

Cardiff Oncology, Inc. Funding & Solvency Profile

CRDF · NASDAQ

Current Assets

Cash & Cash Equivalents17.47M

Net Receivables182.00K

Inventory0.00

Other Current Assets1.64M

Total Current Assets60 M

Non-Current Assets

Property, Plant & Equipment1.21M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets549.00K

Total Non-Current Assets2 M

Total Assets

61.88M

Financial Health Analysis

Current Ratio

3.67x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.36x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

44 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

97% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Cardiff Oncology, Inc. Balance Sheet

CRDF • NASDAQ

Cardiff Oncology, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Jan 2006	Jan 2005
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	17.5M	51.5M	21.7M	16.3M	11.9M	131M	10.2M	11.5M	8.2M	37.9M	67.5M	27.3M	25.8M	10.8M	700.4K	58.7K	550K	-5.6M	-1.1M
Short-Term Investments	40.8M	40.3M	53.2M	88.9M	128.9M	0.0	0.0	0.0	0.0	24M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	58.3M	91.7M	74.8M	105.3M	140.8M	131M	10.2M	11.5M	8.2M	37.9M	67.5M	27.3M	25.8M	10.8M	700.4K	58.7K	550K	-5.6M	-1.1M
Net Receivables	182K	773K	288K	771K	535K	320K	203.5K	167.8K	77.1K	100.5K	98.7K	56.7K	79K	168.4K	99.1K	75K	30K	0.0	0.0
Accounts Receivables	182K	773K	288K	771K	535K	320K	203.5K	167.8K	77.1K	100.5K	98.7K	56.7K	79K	168.4K	99.1K	75K	28K	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-426K	0.0	-228.4K	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	4.8M	2.1M	955K	1.1M	1.2M	956.6K	789.3K	369.3K	152.8K	60K	42.7K	151K	0.0	0.0	0.0
Other Current Assets	1.6M	2.5M	2.3M	5.2M	0.0	0.0	563.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	70K	0.0	0.0
Total Current Assets	60.1M	95.1M	77.4M	111.3M	146.1M	133.4M	11.4M	12.8M	9.5M	39M	68.4M	27.3M	26.1M	10.8M	842.2K	284.7K	650K	-5.6M	-1.1M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	1.2M	2.1M	2.9M	3.5M	3.2M	967K	1.6M	1.3M	2.4M	3.8M	2.7M	840K	750.6K	255K	22.5K	31.3K	10K	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	971.7K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	549K	69K	1.3M	1.4M	239K	404K	-813.7K	103K	390K	1.2M	374K	763K	336.5K	590K	174.6K	196.2K	100K	0.0	0.0
Total Non-Current Assets	1.8M	2.1M	4.2M	4.9M	3.4M	1.4M	1.7M	1.4M	2.8M	5M	3.1M	1.6M	1.1M	845K	197.1K	227.5K	110K	0.0	0.0
Total Assets	61.9M	97.2M	81.6M	116.2M	149.5M	134.7M	13.1M	14.2M	12.3M	44M	71.4M	28.9M	27.2M	11.7M	1M	512.2K	760K	-5.6M	-1.1M
LIABILITIES
CURRENT LIABILITIES
Total Payables	8.1M	4.8M	2M	2M	1.9M	1.8M	656.3K	664.8K	825.2K	1.1M	1M	747.8K	286.6K	175.7K	928.4K	637.9K	826.3K	0.0	0.0
Accounts Payable	8.1M	4.8M	2M	2M	1.4M	1.4M	656.3K	664.8K	825.2K	1.1M	1M	747.8K	286.6K	175.7K	928.4K	637.9K	826.3K	0.0	0.0
Other Payables	0.0	0.0	0.0	0.0	414K	390K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	5.2M	2.7M	3.3M	2.7M	1.9M	2.9M	1.4M	1.1M	4M	1.9M	1.8M	1.5M	554.7K	501.5K	448.7K	0.0	0.0	0.0
Short Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3M	2.4M	5.2M	1.9M	198.2K	0.0	0.0	2.3M	2.1M	0.0	0.0
Capital Lease Obligations (Current)	730K	710K	691K	675K	551K	860K	865.4K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-11.0	-611.0	589.0	-1.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	7.6M	2.7M	5M	1.8M	1.5M	1.6M	365.5K	827.7K	651.2K	285.2K	30.6K	0.0	0.0	0.0	0.0	0.0	270K	0.0	0.0
Total Current Liabilities	16.4M	13.4M	10.4M	7.8M	6.6M	6.1M	4.8M	3M	3.9M	7.8M	8.2M	4.5M	2M	730K	1.4M	3.4M	3.2M	0.0	0.0
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.2M	11.2M	13.1M	323K	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	441K	132.5K	1.1M	1.8M	2.2M	3.3M	3M	4.4M	8.8M	3.8M	2.1M	1.3M	0.0	0.0
Total Non-Current Liabilities	102K	813K	1.5M	2M	2.6M	450K	994K	1.1M	1.8M	16.4M	14.5M	16.1M	4.8M	8.8M	3.8M	2.1M	1.3M	0.0	0.0
Capital Lease Obligations	832K	1.5M	2.1M	2.7M	3.1M	869K	1.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	16.5M	14.2M	11.9M	9.8M	9.1M	6.6M	5.8M	4.1M	5.8M	24.2M	22.7M	20.5M	6.8M	9.5M	5.3M	5.5M	4.6M	0.0	0.0
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	1K	1K	60.0	60.0	60.0	60.0	60.0	60.0	60.0	96.0	96.0	96.0	0.0	2.8M	0.0
Common Stock	7K	7K	4K	4K	4K	4K	8.3K	7.7K	5.3K	3.1K	3K	1.9K	1.9K	1.5K	6.4K	5.3K	0.0	7.1M	5.2M
Additional Paid-In Capital	475.4M	467.1M	409.3M	404.8M	400.5M	361.8M	217.2M	202.3M	179.5M	167.9M	157.6M	89.7M	87.4M	57.4M	38.4M	35.4M	0.0	0.0	0.0
Retained Earnings	-430M	-384.2M	-339.5M	-298.1M	-259.8M	-231.5M	-208.9M	-192.2M	-173M	-148.1M	-108.9M	-81.4M	-67M	-55.2M	-43.6M	-41.3M	-35.8M	0.0	0.0
Accumulated Other Comprehensive Income/Loss	50K	34K	-67K	-395K	-142K	0.0	-971.7K	-2.1M	-2.1M	-10.8K	-854.8K	-533.9K	-348.6K	-259.6K	-221.8K	-211.5K	-200K	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	-139K	-2.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2M	1.2M	32.2M	-9.9M	-5.2M
Total Stockholders' Equity	45.4M	82.9M	69.7M	106.3M	140.4M	128.2M	7.3M	10.1M	6.5M	19.8M	48.7M	8.3M	20.4M	2.2M	-4.2M	-5M	-3.8M	9.9M	5.2M
Total Equity	45.4M	82.9M	69.7M	106.3M	140.4M	128.2M	7.3M	10.1M	6.5M	19.8M	48.7M	8.3M	20.4M	2.2M	-4.2M	-5M	-3.8M	9.9M	5.2M
SUMMARY
Total Liabilities & Equity	61.9M	97.2M	81.6M	116.2M	149.5M	134.7M	13.1M	14.2M	12.3M	44M	71.4M	28.9M	27.2M	11.7M	1M	512.2K	760K	-5.6M	-1.1M
Total Investments	40.8M	40.3M	53.2M	88.9M	128.9M	0.0	971.7K	0.0	0.0	24M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Debt	832K	1.5M	2.1M	2.7M	3.1M	869K	1.7M	0.0	1.3M	16.5M	16.5M	15M	521.2K	0.0	0.0	2.3M	2.1M	0.0	0.0
Net Debt	-16.6M	-49.9M	-19.5M	-13.6M	-8.8M	-130.1M	-8.5M	-11.5M	-6.9M	-21.4M	-51M	-12.3M	-25.3M	-10.8M	-700.4K	2.3M	1.6M	5.6M	1.1M
Shares Outstanding	66,525,854	66,525,854	66,525,854	66,525,854	66,525,854	66,525,854	66,525,854	66,525,854	66,525,854	66,525,854	66,525,854	66,525,854	66,525,854	66,525,854	66,525,854	66,525,854	66,525,854	66,525,854	66,525,854

SEC Filings

CRDF - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 03, 2026	June 03, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 29, 2026	May 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 19, 2026	May 19, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 14, 2026	May 14, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 14, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 23, 2026	June 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 09, 2026	April 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 02, 2026	March 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 25, 2026	February 25, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 24, 2026	February 24, 2026	2026	View Filing

Showing 1 to 10 of 574 filings

Related Guides

Blog Categories

Continue your CRDF research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.